However, for a specific group of people with hypertension, there is currently no systematic conclusion regarding how the polymorphisms of the CYP2C19 gene increase the risk of CAD by influencing metabolic pathways, inflammatory responses, or vascular remodeling [21, 22]. The gene discussed is CYP2C19; the disease is Hypertension.